Lumiphore

Executive Summary

Lumiphore, a privately-held biotechnology company based in Berkeley, California, specializes in advanced chelation technology for medical applications. Founded in 2005, the company has developed proprietary macrocyclic BiFunctional Chelates (mBFCs) that enable the creation of radiotheranostic agents—combining therapeutic and diagnostic capabilities for cancer. Additionally, Lumiphore's platform supports highly sensitive, mix-and-read diagnostic assays using luminescent lanthanide reporters. This dual focus positions the company at the intersection of precision oncology and in vitro diagnostics, with potential applications across both imaging and therapy. Despite a long history since its founding, Lumiphore has maintained a low public profile, with limited disclosed funding or clinical milestones. However, its technology platform could attract strategic partnerships or licensing deals with larger pharmaceutical or diagnostic firms seeking novel chelation chemistry. The company's private status and lack of recent news suggest it may be operating in stealth mode or focusing on R&D and intellectual property development. The conviction score is moderate, reflecting the company's innovative platform but also the lack of publicly verifiable progress, funding, or commercial traction. Without recent updates on clinical trials or partnerships, the risk profile remains elevated. Key catalysts to watch include potential announcements of partnerships with radiopharmaceutical or diagnostic companies, progress towards clinical trials for a lead radiotheranostic candidate, or launch of a commercial diagnostic assay leveraging its lanthanide reporter technology. Given the company's age, an exit via acquisition could also be a possibility if the platform garners interest from industry players.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic partnership or licensing deal for radiotheranostic platform30% success
• H1 2027First clinical trial initiation for a lead mBFC-based radiotheranostic candidate20% success
• Q3 2026Commercial launch of a new diagnostic assay using lanthanide reporters25% success